Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.psym.2018.12.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficient Gene Delivery Admitted by small Metabolites Specifically Targeting Astrocytes in the Mouse Brain.
Mol Ther
January 2025
School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China; Chinese Institute for Brain Research, Beijing 102206, China. Electronic address:
The development of efficient and targeted methods for delivering DNA in vivo has long been a major focus of research. In this study, we introduce a gene Delivery approach Admitted by small Metabolites, named gDAM, for the efficient and targeted delivery of naked DNA into astrocytes in the adult brains of mice. gDAM utilizes a straightforward combination of DNA and small metabolites, including glycine, L-proline, L-serine, L-histidine, D-alanine, Gly-Gly, and Gly-Gly-Gly, to achieve astrocyte-specific delivery of naked DNA, resulting in transient and robust gene expression in these cells.
View Article and Find Full Text PDFA case report of exacerbation of extrapyramidal symptoms following the switch from risperidone to paliperidone during valproate therapy.
BMC Psychiatry
January 2025
Department of Psychiatry, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-Ku, Yokohama, Kanagawa, 236-0004, Japan.
Background: Paliperidone is a second-generation antipsychotic and the main active metabolite of risperidone, formulated to provide consistent therapeutic effects through an extended-release system, designed to provide consistent therapeutic effects through an extended-release formulation. While commonly used in clinical practice, switching from risperidone to paliperidone, particularly during valproate therapy, can pose challenges due to potential pharmacokinetic interactions that may increase the risk of extrapyramidal symptoms (EPS). Despite clinical observations suggesting these interactions, case reports documenting such adverse effects are scarce.
View Article and Find Full Text PDFP300 Event-Related Potential: A Surrogate Marker of Cognitive Dysfunction in Parkinson's Disease Patients with Psychosis.
Ann Indian Acad Neurol
January 2025
Department of Clinical Psychology, National Institute of Mental Health and Neuro Sciences, Bengaluru, Karnataka, India.
Background And Objectives: Psychosis is one of the major neuropsychiatric non-motor symptoms of Parkinson's disease (PD). Prolonged latency and decreased amplitude of the P300 event-related potential (ERP) is a potential neurophysiologic biomarker of deeper neurocognitive deficits in PD. We aimed to characterize electroencephalogram (EEG)/ERP parameters in PD patients with and without psychosis (PDP and PDNP, respectively), and to determine if such measures could act as endophenotypes for PD-associated psychosis (PDP).
View Article and Find Full Text PDFThe impact of the COVID-19 pandemic on hospital admissions in a psychiatric ward in a general hospital in Greece.
Psychiatriki
December 2024
Mobile Mental Health Unit of the prefectures of Ioannina and Thesprotia, Society for the Promotion of Mental Health in Epirus, Ioannina, Greece.
Article Synopsis
- The COVID-19 pandemic has negatively impacted the mental health and treatment engagement of patients, leading to significant declines in voluntary attendance at psychiatric services.
- A study in Corfu, Greece, analyzed psychiatric ward attendance and admissions over a 12-month period post-pandemic compared to pre-pandemic data, revealing a 26.5% drop in voluntary patient attendance.
- Additionally, while the length of hospital stays increased by 13.2%, involuntary commitments and overall admission rates remained stable, highlighting differentiated effects on various psychiatric diagnoses.
Association of abnormal cortical inhibition and clinical outcomes in patients at clinical high risk for psychosis.
Clin Neurophysiol
January 2025
Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address:
Article Synopsis
- Cortical inhibition (CI) abnormalities were investigated in individuals at clinical high risk for psychosis (CHR) using transcranial magnetic stimulation (TMS), comparing them to first-episode schizophrenia (FES) patients and healthy controls (HC).
- Among CHR individuals, those who later developed schizophrenia (CHR-C) exhibited a longer cortical silent period (CSP) compared to healthy controls, while those who did not convert (CHR-NC) had similar CSP levels to HC.
- The study indicates that prolonged CSP in CHR-C patients is linked to poorer neurocognitive performance and suggests CSP may serve as a biomarker for predicting the transition to schizophrenia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!